prof. Vibeke Kruse (MD, PhD)

CRIG member
Vibeke Kruse

Head of Clinical - Medical Oncology (UZ Gent)
Member of the ION (Immuno-Oncology Network) steering Commitee


Research focus

  • Tumor immunology with focus on melanoma and indoleamine-2,3-dioxygenase (IDO)
  • Clinical research in melanoma (evaluation of new drugs and/or new drug combinations, research on biomarkers, new imaging techniques)
  • Clinical research focusing on immunotherapy in general and the management of immune related adverse events (iRAE) (development of a database, biobanking, design of clinical care paths for high risk sub-populations,…)
  • Patient-centered melanoma care focusing on more psychosocial aspects of cancer care


Research team



  • Medical Doctor (MD) - Faculty of Medicine & Health Sciences, Aarhus University, Denmark (2005)
  • Board Certified medical oncologist (03/2013) - Department of Medical Oncology, University Hospital Ghent, Belgium
  • Board Certified Clinical Pharmacologist (2014) - Dutch Society for Clinical Pharmacology & Biopharmacy, University Nijmegen/Utrecht, The Netherlands 
  • PhD from the Faculty of Medicine and Health Sciences, University of Ghent (2014)
  • Postgraduate training ‘Hospital Management’ University of Ghent (2015)

Key publications

  • The Rationale of IDO Inhibition for Cancer Therapy. European Journal of Cancer, 2017. (PMID: 28324751)
  • A phase 2 clinical trial on the combination of dabrafenib plus trametinib for BRAF(+MEK)-inhibitor pretreated patients with advanced BRAFV600-mutant melanoma. Lancet Oncology, 2017. (PMID: 28268064)
  • A phase II trial of stereotactic body radiotherapy with concurrent anti-PD1 treatment in metastatic melanoma: evaluation of clinical and immunologic response. Journal of Translational Medicine, 2017. (PMID: 28137295)
  • Successful strategy to treat a solitary cystic melanoma brain metastasis. Journal of the European Academy of Dermatology and Venereology, 2016. (PMID: 27684056)
  • Copy number variation analysis and methylome profiling of a GNAQ-mutant primary meningeal melanocytic tumor and its liver metastasis. Experimental and Molecular Pathology, 2017. (PMID: 27974237)
  • Ipilimumab, not just another anti-cancer therapy: hypophysitis toxicity illustrated by four case-reports. Endocrine, 2014. (PMID: 24554495)
  • Systemic immune changes associated with adjuvant interferon-α2b-therapy in stage III melanoma patients: failure at the effector phase? Melanoma Research, 2015. (PMID: 26050145)
  • Peritumoral indoleamine 2,3-dioxygenase expression in melanoma: an early marker of resistance to immune control? British Journal of Dermatology, 2014.  (PMID: 24814041)
  • Reproducibility of FDG PET based Metabolic Tumor Volume Measurements and of Their FDG Distribution Within. Quarterly Journal of Nuclear Medicine and Molecular Imaging,  2015 PMID: 24695005
  • Imaging Requirements for Personalized Medicine: The Oncologists Point of View. Current Pharmaceutical Design, 2013 Sep 11. PMID: 24025098


ION - Immuno-Oncology Network - Gent - Belgium
Kankercentrum Gent